1.1 The Stryker Proposition: Resilience in a Volatile Era

Stryker Corporation enters the 2026 fiscal year as a paradigm of operational excellence within the global medical technology sector, distinguished by its relentless organic growth profile and strategic capital deployment. Having concluded Fiscal Year 2025 with record-breaking revenues exceeding $25.1 billion and adjusted earnings per share (EPS) of $13.63, the company has firmly established itself not merely as a participant in the medtech landscape but as a bellwether for the industry's health. The company's performance is characterized by a "supercycle" of innovation, particularly in robotic-assisted surgery and digital healthcare ecosystems, which has allowed it to consistently outperform peer growth rates by substantial margins.

The investment thesis for St ...